A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

• Key Inclusion Criteria:

1. The participant has completed TAK-079-3002 (end of trial [EOT]) or TAK-079-1004 (EOT). Participants from TAK-079-1004 must have had a response to mezagitamab asdemonstrated by meeting the criteria for "platelet response" specified for thattrial during either the main study or open-label extension.

• Key Exclusion criteria:

For TAK-079-3002 participants:

1. The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab formulation.

For TAK-079-1004 participants:

1. The participant has had any thrombotic or embolic event within 12 months beforesigning the ICF.

2. The participant has had a splenectomy within 3 months before signing the ICF.

3. The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

4. History of malignancy (including myelodysplastic syndrome) within 5 years of signingthe ICF, except for treated non-melanoma skin cancer or cervical carcinoma in situ.

5. In the opinion of the investigator, the participant has a serious medical orpsychiatric illness that could potentially interfere with the completion oftreatment according to this protocol.

6. The participant has received anti-cluster of differentiation (CD) 20 treatmentwithin 12 months before screening and either of the following applies:

7. The last dose was received within 6 months before screening.

8. The last dose was received between 6 and 12 months before screening and theparticipant has a CD19+ count below the lower limit of normal.

9. The participant has received any monoclonal or polyclonal antibody forimmunomodulation within 6 months before Visit 1.

10. The participant has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.

11. The participant has used anticoagulants (for example, vitamin K antagonists, directoral anticoagulants) within 3 weeks prior to Visit 1.

10 The participant has received a live or live-attenuated vaccine within 4 weeks prior to the first dose of trial treatment or has any live or live-attenuated vaccine planned during the trial.

11. The participant has used the following immunosuppressive agents as specified prior to Visit 1: alkylating agents (for example, cyclophosphamide) within 8 weeks, vinca alkaloids (for example, vincristine) within 4 weeks, sulfones (for example, dapsone) within 3 weeks, antiproliferative agents: (for example, mycophenolate mofetil and azathioprine) within 2 weeks, and calcineurin inhibitors: (for example, cyclosporine) within 2 weeks.

12. The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab formulation.

Other protocol defined inclusion/exclusion criteria may apply.